Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: sector rebounds after a tough February

March 1, 2021 5:04pm

As sentiment was boosted by of Johnson & Johnson’s (JNJ) advisory panel approval

While the $1.9 trillion fiscal aid/stimulus bill after a House narrow approval now moves to the Senate which expects to propose amendments

Pre-open indication results: 8 HITs and 2 MISS

The Dow closed UP +603.14 points (+1.95%); the S&P closed UP +90.67 points (+2.38%) while the Nasdaq closed UP +396.48 points (+3.01%)

Henry’omics:

Indexes jumped sharply on Monday as Treasury yields retreated…

Sector breadth was strong on Monday with only about 6 stocks trading lower of the 35 covered.

On the stimulus front, the House passed a $1.9 trillion COVID-19 relief bill, the American Rescue Plan Act of 2021, early Saturday. The Senate will now consider the legislation.

RegMed Investors’ (RMi) pre-open: “a new month, rotating with a sentiment boost. The CDC and Prevention advisory panel voted unanimously Sunday to recommend the use of Johnson & Johnson’s (JNJ) one-shot Covid-19 vaccine for people 18 years of age and older. The company expects to ship out 4 million of doses initially.” … https://www.regmedinvestors.com/articles/11790

Pre-open indication results: 8 HITs < SELL: Biostage (BSTG -$0.01 with 1,838 shares traded); BUY: Applied Genetic Technologies (AGTC +$0.43), CRISPR Therapeutics (CRSP +$4.56), Editas Medicine (EDIT +$3.03), Intellia Therapeutics (NTLA +$3.57), Voyager Therapeutics (VYGR +$0.30); SELL: Precigen (PGEN -$0.24), Mesoblast (MESO -$0.00) and 2 MISS: BUY: bluebird bio (BLUE -$1.02), Global Blood Therapeutics (GBT +$1.88)

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …

Monday opened positive at 26/6, 2 flat and 1 acquired, stayed positive at the mid-day to 26/6, 2 flat and 1 acquired, closing positive at 27/6, 1 flat and 1 acquired;
Friday opened negative at 4/27, 3 flat and 1 acquired, flipped positive at the mid-day to 18/15, 1 flat and 1 acquired, closing positive at 18/15, 1 flat and 1 acquired;

There are clear winners — and losers — heading into the second month and Q1 of 2021.

Jumping with share pricing momentum:

Fate Therapeutics (FATE), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Editas Medicine (EDIT) Sage Therapeutics (SAGE) to name 5 of the 27 inclining of the 35 covered

Hammered in today’s market:

ReNeuron (RENE.L), bluebird bio (BLUE), Precigen (PGEN), Pluristem (PSTI), Vericel (VCEL), Bellicum Pharmaceuticals (BLCM) to name 6 of the 6 declining of the 35 covered

Key metrics:

Sector volume was LOW with 1 of the 27-upside having higher than the 3-month average volume with the increased volume of 2 of 6-downside having higher than the 3-month average volume;

Monday’s percentage (%) of the 27-upside were +0.44% (ALNY) to +8.46% (AGTC) while the 6-downside ranges from -0.23% (VCEL) to -5.41% (RENE.L);

Monday’s (10 of 27) incline

Fate Therapeutics (FATE +$6.89 after Friday’s +$3.45);
CRISPR Therapeutics (CRSP +$4.56 after Friday’s -$1.59);
Intellia Therapeutics (NTLA +$3.57 after Friday’s +$2.99);
Editas Medicine (EDIT +$3.03 after Friday’s -$0.90);
Sage Therapeutics (SAGE +$2.71 after Friday’s +$1.55);
Global Blood Therapeutics (GBT +$1.88 after Friday’s -$0.90);
Ionis Pharmaceuticals (IONS +$1.65 after Friday’s -$1.01);
Regenxbio (RGNX +$1.60 after Friday’s +$0.93);
BioLife solutions (BLFS +$1.45);
uniQure NV (QURE +$1.35 after Friday’s -$0.30);

Monday’s (6 of 6) decliners:

ReNeuron (RENE.L -$6.00 after Friday’s -$2.00);
bluebird bio (BLUE -$1.02);
Precigen (PGEN -$0.24);
Pluristem (PSTI -$0.13);
Vericel (VCEL -$0.11 after Friday’s +$0.71);
Biostage (BSTG -$0.01 after Friday’s -$0.15);

Closing 1 – Mesoblast (MESO), and 1 - Stemline Therapeutics (STML – acquired)

Sentiment and COVID-19 infections:

Johnson & Johnson (JNJ) has begun shipping out nearly 4 million doses of its Covid-19 vaccine

Infection cases <Million>: never to forget …

Monday 28.61 M cases,
Monday’s death rate totaled 513,510 <Johns Hopkins University>

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

Monday, the IBB closed up +1.73% and XBI closed up +2.43%
Friday, the IBB closed down -0.14% and XBI closed up +0.76%

The CBOE Volatility Index (VVIX: INDEX) tracked:

Monday was down -4.60points or -16.46% at 23.25
Friday was down -0.94 points or -3.25% at 27.95

Upside volume: low

Monday: 1 out of the 27-upside had higher than the 3-month average volume;
Friday: 6 out of the 18-upside had higher than the 3-month average volume;

Downside volume: low

Monday: 2 out of the 6-downside had higher than the 3-month average volume;
Friday: 5 out of the 15-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: % and pricing drop

Monday’s percentage (%) of the 27-upside were +0.44% (ALNY) to +8.46% (AGTC) while the 6-downside ranges from -0.23% (VCEL) to -5.41% (RENE.L);
Friday’s percentage (%) of the 18-upside were +0.48% (PSTI) to +10.60% (BLUE) while the 15-downside ranges from -0.42% (VSTM) to -8.99% (VYGR);

March, the 3^rd month of Q1/21:

Monday (3/1) closed positive with 27 advancers, 6 decliners, 1 flat and 1 acquired

The BOTTOM LINE: I am STILL sending up a red flag on stock pricing until earnings’’ season completes its run.

There is always a shift going-on however, these last two (2) months continues to leave me … QUESTIONING staying longer than a WEEK as I have said recently - my horizon on Monday is to meet on Friday.

As to earnings’ season: “Again, “forewarned … earnings LPS (loss-per-share) season is upon us – my advice, trim and skim … if one can!”

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.